Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Incremental research runs every 3 hours. Verified updates are published when qualifying developments are found. Editorial standards · RSS ↗
Teva announced FDA approval of WELTRUZA, a monthly subcutaneous extended-release olanzapine suspension for adults with schizophrenia. The formulation uses Medincell’s SteadyTeq copolymer technology and requires no loading dose, oral supplementation, or post-injection monitoring. Supported by the Phase 3 SOLARIS trial, it retains important olanzapine safety considerations, including weight gain and metabolic effects, rather than eliminating systemic drug risks.
Johnson & Johnson reported Week 112 results from ICONIC-LEAD in adults and adolescents with moderate-to-severe plaque psoriasis. The company said skin clearance and patient-reported improvements remained sustained, with no new safety signals identified. The update adds longer-term evidence for an oral IL-23 receptor peptide, although company-reported follow-up does not eliminate ongoing safety monitoring needs.
Circular RNA nanoparticles encoding the malaria transmission antigen Pvs25 were compared with a modified linear mRNA vaccine in mice. Both platforms induced antigen-specific responses, and booster immunization generated antibodies that blocked parasite development in mosquito assays. The findings support further evaluation of circular RNA for transmission-blocking vaccination, without establishing greater efficacy, durability, or manufacturing economy than linear mRNA in humans.
A new review surveys pharmaceutical cocrystals beyond the commonly studied 1:1 stoichiometry, covering preparation methods, characterization, and relationships between composition and physical properties. It discusses solution crystallization, mechanochemistry, and vapor-induced transformations alongside challenges in formation-rule prediction, metastable-phase stabilization, and scale-up. This is a research synthesis, not a new clinical result or regulatory endorsement of particular cocrystal products.
Ritedose has opened an analytical chemistry laboratory alongside expanded microbiology facilities, tripling its laboratory footprint through an investment exceeding $17 million. Capabilities include extractables and leachables, nitrosamine testing, drug product characterization, and ten qualified ICH stability chambers. The infrastructure supports development, regulatory submissions, release testing, and lifecycle management for its sterile blow-fill-seal ophthalmic and respiratory manufacturing programs.
Roche entered a research collaboration and licensing agreement with Hangzhou-based Defand Therapeutics to discover molecular glue degraders for oncology and immunology targets. Defand will contribute its screening platform, with Roche taking responsibility for subsequent development and exclusive global commercialization. The announcement did not disclose upfront payment amounts, milestone thresholds, or royalty rates.
Nurix announced the first patient enrollment in NX-5948-203, a Phase 1b/2 trial combining the investigational BTK degrader bexobrutideg with venetoclax in chronic lymphocytic leukemia. Initial enrollment focuses on relapsed or refractory disease. Conducted under the Roche collaboration, the study will assess safety, tolerability, and clinical activity to inform potential combination development across treatment settings.
Arvinas presented final Phase 1 findings for its brain-penetrant LRRK2 degrader ARV-102 in 24 patients with Parkinson’s disease treated for 28 days. Exploratory changes in eye movement measurements correlated with reductions in cerebrospinal fluid LRRK2 and changes in pathway biomarkers. The trial was not designed to establish clinical efficacy or effects on disease progression.
Researchers characterized PSIRC3, an irreversible covalent BTK PROTAC that produced rapid, selective degradation in cellular experiments and target reduction in vivo. Activity required engagement of BTK Cys481 and was lost against the C481S mutant. Modeling supported a balance between target and E3 ligase affinities, challenging the assumption that catalytic turnover is required for potent degradation.
Researchers studied flurbiprofen–polyvinylpyrrolidone amorphous solid dispersions using controlled nucleation and real-time synchrotron X-ray diffraction after contact with water. Higher nucleation density shortened the lag before crystallization and accelerated drug crystallization. The work proposes that evaluating latent nuclei is important to maintaining supersaturation, rather than assuming the absence of visible crystals demonstrates a robust amorphous formulation.
GEA has introduced the ConsiGma FC Flex, a production-scale film coater for tablets, capsules, and pellets. It processes approximately nine-kilogram sub-batches in six-minute cycles and retains the laboratory system’s drum diameter while changing drum depth and nozzle count. Standard containment targets OEB 4, with an optional cleaning upgrade supporting OEB 5–6 applications, according to the supplier.
Viking began an exploratory study evaluating oral and less frequent injectable VK2735 maintenance strategies after initial weekly injections. Approximately 195 adults are expected to participate, with maintenance evaluated through Week 33 and results anticipated in 2027. This adjacent oral peptide delivery study has not established successful weight maintenance; a later correction clarified the oral dosing schedule.
Continue your research
All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.
